Rheopheresis® for age-related macular degeneration;Rheopherese® bei Altersbedingter Makuladegeneration

Ophthalmologe

Volumn 106, Issue 2, 2009, Pages 127-132

  Wild, C ^a   Mathis, S ^a   Guba, B ^a   Gartlehner, G ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Age related macular degeneration; Apheresis; Evidence based medicine; Health technology assessment; Reimbursement

Indexed keywords

HUMAN; META ANALYSIS; METHODOLOGY; PLASMAPHERESIS; PREVALENCE; RETINA MACULA DEGENERATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; UTILIZATION REVIEW;

HUMANS; MACULAR DEGENERATION; PLASMAPHERESIS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 67349212312     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-008-1768-1     Document Type: Article

References (29)

1. Arbeitsausschuss .,Ärztliche Behandlung" des Bundesausschusses der Ärzte und Krankenkassen (2003) Therapeutische Hämapheresen (selektive Verfahren mit Plasmadifferentialtrennung). Köln
2. Bach 1998 Klin Monatsbl Augenheilkd 212 190
3. Brunner 2000 Retina 20 483
4. Bundesverband Medizintechnologie e.V. (2001) Die Therapeutische Apherese - der Einsatz innovativer extrakorporaler Therapieverfahren. http://www.bvmed.de/stepone/data/downloads/33/a4/00/AphereseBroschueredt2001. pdf [Zugriff am Feb 6 2008]
5. Clemons 2005 Ophthalmology 112 533
6. ClinicalTrials.gov Long-term efficacy in AMD of Rheopheresis in North America. NCT00380172. U.S. National Institutes of Health. http://www. clinicaltrials.gov/ct2/show/NCT00380172?spons=%22OccuLogix%22&spons-ex= Y&rank=3 [Zugriff am Feb 6 2008]
7. ClinicalTrials.gov Safety and effectiveness investigation for dry, non-exudative age related macular degeneration (AMD) using rheopheresis (RHEO-AMD). NCT00460967. U.S. National Institutes of Health. http://www.clinicaltrials.gov/ct2/show/NCT00460967?spons=%22OccuLogix%22& spons-ex=Y&rank=2 [Zugriff am Feb 6 2008]
8. Comer 2004 Drugs Aging 21 967
9. Congdon 2004 Arch Ophthalmol 122 477
10. Donaldson 2006 Curr Opin Ophthalmol 17 267
11. Evans JR (1998) Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane database of systematic reviews, Art. No. CD000254 http://www.cochrane.org/reviews/en/ ab000254.html [Zugriff am Feb 11 2008]
12. Fine 2000 N Engl J Med 342 483
13. Gartlehner G (2007) Internes Manual. Abläufe und Methoden, Teil 2. Ludwig Boltzmann Institut, Wien. http://eprints.hta.lbg.ac.at/713/
14. Klingel 2005 J Clin Apher 20 169
15. Klingel 2003 Transfus Apher Sci 29 71
16. Klingel 2002 Ther Apher 6 271
17. Klingel 2003 Ther Apher Dial 7 444
18. Klingel R, Wong D, Fassbender C et al. (2005) Rheopheresis for dry age-related macular degeneration (AMD) - reference controlled RheoNet-registry analysis of safety and efficacy. In: American Society for Apheresis (Hrsg) Presentation, 26th Annual Meeting, 27.-30.04.2005, Chicago
19. Klingel R, Wong D, Fassbender C et al. (2005) Safety and efficacy of rheopheresis for age-related macular degeneration (AMD). Reference controlled RheoNet-registry analysis. Invest Ophthalmol Vis Sci 46: E-Abstract 2368. http://abstracts.iovs.org/cgi/content/abstract/46/5/2368
20. Lüke 2001 J Clin Apher 16 23
21. Lüke 2003 Ther Apher Dial 7 263
22. Pro Retina Deutschland e.V. (2005) Rheopherese zur Behandlung der Altersabhängigen Makuladegeneration. Stellungnahme des Arbeitskreises Klinische Fragen der Pro Retina. http://www.pro-retina.de/deu/forschung/ wissenschaftliche-beratungsgremien/empfehlungen/rheopherese.html [Zugriff am Feb 6 2008]
23. Pulido 2002 Trans Am Ophthalmol Soc 100 85
24. Pulido 2005 Can J Ophthalmol 40 332
25. Pulido 2005 J Clin Apher 20 168
26. Pulido 2006 Trans Am Ophthalmol Soc 104 221
27. TM An Overview of the Rheo Procedure. OccuLogix, Inc. http://www.rheo.com/page.cfm?id=494974C6-7B48-4087-8FA8-4BB40E2154B5&path= MD [Zugriff am Feb 6 2008]
28. Szczepiorkowski 2007 J Clin Apher 22 106
29. Vuylsteke 2003 Lancet 362 1720